Evidence map›Paper›PMID 35035814›Full record

ArticleJournal of healthcare engineering2022

circRNA LDLRAD3 Enhances the Malignant Behaviors of NSCLC Cells via the miR-20a-5p-SLC7A5 Axis Activating the mTORC1 Signaling Pathway.

Yu Li, Guangle Qin, Jinyun Du, Peng Yue, Yanling Zhang, Na Hou

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yu LiDepartment of ICU Medicine, Shandong Province Zibo No. 1 Hospital, Zibo 255200, Shandong, China.ORCID 0000-0001-6192-3771
Guangle QinEmergency Department, Shandong Province Zibo No. 1 Hospital, Zibo 255200, Shandong, China.ORCID 0000-0002-1073-592X
Jinyun DuDepartment of ICU Medicine, Shandong Province Zibo No. 1 Hospital, Zibo 255200, Shandong, China.ORCID 0000-0001-9422-925X
Peng YueEmergency Department, Shandong Province Zibo No. 1 Hospital, Zibo 255200, Shandong, China.ORCID 0000-0002-2841-8885
Yanling ZhangDepartment of Intensive Care, Boxing County Hospital of Traditional Chinese Medicine, Binzhou 256500, Shandong, China.ORCID 0000-0003-4135-9696
Na HouOncology Dept. II, Shandong Province Zibo No. 1 Hospital, Zibo 255200, Shandong, China.ORCID 0000-0001-8330-0858
Central Hospital of Zibo · CNBoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNA LDLRAD3 behaved as an oncogene in several malignancies, but its effects in NSCLC and the involvement of downstream molecules and activation of signaling pathways had not been fully reported. We planned to explore how LDLRAD3 facilitated the malignancy of NSCLC. QRT-PCR was performed to evaluate the expression levels of LDLRAD3, miR-20a-5p, and SLC7A5 in NSCLC tissues and cells. si-LDLRAD3 was transfected to A549 and H1299 cells to knock down intrinsic LDLRAD3 to determine its oncogenic roles. CCK-8 assay and transwell assay were executed to assess cell proliferative, migrative, and invasive abilities. Dual-luciferase reporter (DLR) assay was manipulated to verify the ENCORI-predicted relationships between LDLRAD3 and miR-20a-5p and between miR-20a-5p and SLC7A5. Western blot, immunofluorescent assay, and immunohistochemistry were applied to explore the expression levels of SLC7A5, and the levels of mTORC1 pathway-related proteins were evaluated using western blot. Rescue experiments were conducted by transfecting si-LDLRAD3, miR-20a-5p inhibitor, and si-SLC7A5 to explore the influence of the LDLRAD3-miR-20a-5p-SLC7A5 axis on the malignant behaviors of NSCLC cells. The expression levels of LDLRAD3 and SLC7A5 were boosted, whereas miR-20a-5p was impeded in NSCLC tissues and cell lines. Knockdown of LDLRAD3 weakened the proliferation, migration, and invasion of A549 and H1299 cells. LDLRAD3 was verified to sponge miR-20a-5p and miR-20a-5p targeted SLC7A5. LDLRAD3 activated the mTORC1 singling pathway via the miR-20a-5p-SLC7A5 axis to strengthen the malignant properties of A549 and H1299 cells. We concluded that LDLRAD3 exerted oncogenic effects via the miR-20a-5p-SLC7A5 axis to activate the mTORC1 signaling pathway in NSCLC. Our findings enlightened that LDLRAD3 could become a potential therapeutic target in the treatment and management of NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLarge Neutral Amino Acid-Transporter 1Lung NeoplasmsMechanistic Target of Rapamycin Complex 1MicroRNAsRNA, CircularCell ProliferationHumansSignal TransductionLarge Neutral Amino Acid-Transporter 1Mechanistic Target of Rapamycin Complex 1MicroRNAsMIRN20a microRNA, humanRNA, CircularSLC7A5 protein, human

Identifiers

PMID35035814
PMCPMC8758255
OpenAlexW4205580332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.